Financial News
Articles published by Gilead Sciences, Inc.
![](https://mms.businesswire.com/media/20231102250720/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20231101902559/en/1933118/5/5378214cGCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20231030344859/en/836069/5/NEW_KITE_COLOR_LOGO.jpg)
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20231024925091/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20231020411202/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20231019448510/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20231018296628/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20231017843279/en/1917163/5/2019_AssemblyBio_logo_RGB.jpg)
![](https://mms.businesswire.com/media/20231015111917/en/836069/5/NEW_KITE_COLOR_LOGO.jpg)
![](https://mms.businesswire.com/media/20231015973270/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20231012069243/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 12, 2023
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20231002581798/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20231002292467/en/778437/5/GCP_Primarylarge_1.jpg)
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20230918133960/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20230918662167/en/836069/5/NEW_KITE_COLOR_LOGO.jpg)
![](https://mms.businesswire.com/media/20230909895203/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20230907463986/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead Prices $2 Billion of Senior Unsecured Notes
September 07, 2023
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20230823245751/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20230823013787/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead Sciences to Present at Upcoming Investor Conferences
August 23, 2023
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20230820242621/en/778437/5/GCP_Primarylarge_1.jpg)
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20230816668295/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20230814981551/en/1867352/22/Tentarix_logo.jpg)
![](https://mms.businesswire.com/media/20230802165242/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead Sciences Announces Second Quarter 2023 Financial Results
August 03, 2023
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20230726933349/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20230724915750/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20230723794099/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20230720298935/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20230721916957/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
July 21, 2023
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20230719021635/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
July 20, 2023
Via Business Wire
Tickers
GILD
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.